[The use of aminoglutethimide (orimeten) in disseminated breast cancer]

Administration of orimeten (aminoglutethimide), for disseminated breast cancer in 38 postmenopausal females, in whom other treatment modalities had failed, proved effective in 39%. Patients who had failed on tamoxifen responded to orimeten. Such side-effects as skin rash, drowsiness and cardiovascular disturbances were not pronounced. Limiting toxicity was 6%.